Revolution Medicines, Inc. (NASDAQ: RVMD) is capturing investor attention with its innovative approach to treating RAS-addicted cancers and its enticing potential upside of 26.62%. As a clinical-stage precision oncology company, Revolution Medicines is at the forefront of developing novel targeted therapies that could significantly impact the biotechnology sector.

**Company Overview and Market Position**

Headquartered in Redwood City, California, Revolution Medicines operates within the healthcare sector, focusing specifically on biotechnology. With a substantial market capitalization of $18.62 billion, the company has established itself as a significant player in the pursuit of targeted cancer therapies. The current stock price…